Janus Henderson Group PLC raised its position in Heron Therapeutics Inc (NASDAQ:HRTX) by 2.2% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,767,495 shares of the biotechnology company’s stock after purchasing an additional 126,039 shares during the quarter. Janus Henderson Group PLC owned approximately 10.58% of Heron Therapeutics worth $93,145,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also recently modified their holdings of the company. Legal & General Group Plc grew its stake in Heron Therapeutics by 13.9% in the first quarter. Legal & General Group Plc now owns 8,971 shares of the biotechnology company’s stock valued at $136,000 after purchasing an additional 1,098 shares in the last quarter. Quantbot Technologies LP boosted its stake in shares of Heron Therapeutics by 2,619.6% during the 2nd quarter. Quantbot Technologies LP now owns 12,483 shares of the biotechnology company’s stock worth $172,000 after acquiring an additional 12,024 shares in the last quarter. Trexquant Investment LP bought a new stake in shares of Heron Therapeutics during the 3rd quarter worth about $206,000. Jane Street Group LLC bought a new stake in shares of Heron Therapeutics during the 3rd quarter worth about $223,000. Finally, HighTower Advisors LLC boosted its stake in shares of Heron Therapeutics by 11.4% during the 2nd quarter. HighTower Advisors LLC now owns 16,584 shares of the biotechnology company’s stock worth $231,000 after acquiring an additional 1,700 shares in the last quarter.
Heron Therapeutics Inc (HRTX) opened at $15.40 on Friday. Heron Therapeutics Inc has a twelve month low of $12.21 and a twelve month high of $18.40. The company has a debt-to-equity ratio of 0.62, a quick ratio of 2.02 and a current ratio of 2.12.
Several analysts have recently issued reports on HRTX shares. Cantor Fitzgerald set a $31.00 price target on Heron Therapeutics and gave the stock a “buy” rating in a research note on Thursday, October 26th. ValuEngine raised Heron Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, November 30th. Northland Securities started coverage on Heron Therapeutics in a research report on Wednesday, September 27th. They set an “outperform” rating and a $40.00 price objective for the company. Mizuho reissued a “buy” rating and set a $28.00 price objective on shares of Heron Therapeutics in a research report on Friday, December 8th. Finally, Noble Financial reissued a “buy” rating and set a $24.00 price objective on shares of Heron Therapeutics in a research report on Friday, October 6th. Two investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. Heron Therapeutics presently has an average rating of “Buy” and a consensus price target of $28.73.
COPYRIGHT VIOLATION NOTICE: “Janus Henderson Group PLC Purchases 126,039 Shares of Heron Therapeutics Inc (HRTX)” was originally published by Community Financial News and is owned by of Community Financial News. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece of content can be viewed at https://www.com-unik.info/2017/12/15/janus-henderson-group-plc-purchases-126039-shares-of-heron-therapeutics-inc-hrtx.html.
Heron Therapeutics Profile
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
What are top analysts saying about Heron Therapeutics? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Heron Therapeutics and related companies.